Mersana Therapeutics, Inc. (MRSN) Earnings History
Annual and quarterly earnings data from 2015 to 2024
Loading earnings history...
MRSN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MRSN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -181.1% | -170.9% |
| 2023 | 100.0% | -463.9% | -465.8% |
| 2022 | 100.0% | -766.6% | -768.3% |
| 2021 | 100.0% | -392693.0% | -395488.4% |
| 2020 | -7996.1% | -18737.4% | -10633.5% |
Download Data
Export MRSN earnings history in CSV or JSON format
Free sign-in required to download data
Mersana Therapeutics, Inc. (MRSN) Earnings Overview
As of May 8, 2026, Mersana Therapeutics, Inc. (MRSN) reported trailing twelve-month net income of -$70M, reflecting +61.8% year-over-year growth. The company earned $-14.05 per diluted share over the past four quarters, with a net profit margin of -170.9%.
Looking at the long-term picture, MRSN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2016.
Mersana Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), SNDX (-$243M net income, -165.6% margin), AGEN ($115,000 net income, 0.1% margin), MRSN has room to improve margins relative to the peer group. Compare MRSN vs RCUS →
MRSN Earnings vs Peers
Earnings metrics vs comparable public companies
MRSN Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$69M | +59.7% | -$73M | $-14.12 | -170.9% | -181.1% |
| 2023 | -$172M | +15.9% | -$171M | $-36.96 | -465.8% | -463.9% |
| 2022 | -$204M | -20.1% | -$204M | $-54.51 | -768.3% | -766.6% |
| 2021 | -$170M | -93.2% | -$169M | $-60.24 | -395488.4% | -392693.0% |
| 2020 | -$88M | -212.1% | -$155M | $-35.80 | -10633.5% | -18737.4% |
| 2019 | -$28M | +56.1% | -$30M | $-16.21 | -67.0% | -71.7% |
| 2018 | -$64M | -66.0% | -$66M | $-69.75 | -606.5% | -619.7% |
| 2017 | -$39M | -182.5% | -$40M | $-42.95 | -220.6% | -225.8% |
| 2016 | -$14M | +16.6% | -$14M | $-19.58 | -54.4% | -54.9% |
| 2015 | -$16M | - | -$16M | $-23.48 | -158.6% | -157.7% |
See MRSN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRSN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRSN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRSN — Frequently Asked Questions
Quick answers to the most common questions about buying MRSN stock.
Is MRSN growing earnings?
MRSN EPS is $-14.05, with earnings growth accelerating to +61.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-70M.
What are MRSN's profit margins?
Mersana Therapeutics, Inc. net margin is -170.9%, with operating margin at -181.1%. Below-average margins reflect competitive or cost pressures.
How consistent are MRSN's earnings?
MRSN earnings data spans 2015-2024. The accelerating earnings trend is +61.8% YoY. Historical data enables comparison across business cycles.